Ketamine may exert antidepressant effects via mediating the kynurenine pathway

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 12, 2011, Pages 1423-1424

  Yang, Chun ^a   Zhou, Zhiqiang ^a   Shi, Jinyun ^a   Yang, Jianjun ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; KETAMINE; KYNURENINE;

DEPRESSION; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; LETTER; PATHOGENESIS; SCHIZOPHRENIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE;

EID: 83655193183     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.641380     Document Type: Letter

References (5)

1. Chopra K, Kumar B, Kuhad A. Pathobiological targets of depression. Expert Opin Ther Targets 2011;15:379-400
2. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol. Ther. 2009;123:143-50
3. Christmas DM, Potokar J, Davies SJ.A biological pathway linking inflammation and depression: Activation of indoleamine 2,3-dioxygenase. Neuropsychiatr Dis Treat 2011;7:431-9
4. Yang JJ, Zhou ZQ, Yang C. Letter to the editor: Does ketamine exert a fast-acting antidepressant effect via inhibition of pro-inflammatory cytokines? Psychol Med 2011;41:1787-9
5. Laugeray A, Launay JM, Callebert J, et al. Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-like behaviours in mice: Focus on individual differences. Pharmacol. Biochem. Behav. 2011;98:161-8